Eli Lilly offers higher Zepbound weight loss drug doses on LillyDirect

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without … Read more

Athenahealth to offer Abridge’s AI scribe to its network of thousands of doctors

A doctor looks at an AI-generated clinical note. Courtesy of Athenahealth Health-care software vendor Athenahealth on Tuesday said it will offer Abridge’s artificial intelligence scribing tool to its network of more than 160,000 clinicians.  Athenahealth has developed an electronic health record, revenue cycle management tools and patient engagement tools for ambulatory care providers, which include … Read more

FDA says Wegovy and Ozempic shortage resolved; Hims & Hers stock falls

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters The long-running U.S. shortage of Novo Nordisk‘s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the U.S. Food and Drug Administration said Friday.  The FDA’s decision will threaten the … Read more

UnitedHealth faces DOJ investigation, buyouts, stock price drop

FILE PHOTO: The logo of Down Jones Industrial Average stock market index listed company UnitedHealthcare is shown in Cypress, California April 13, 2016.  Mike Blake | Reuters UnitedHealthcare is in hot water again as the insurance giant grapples with a reported government investigation of its Medicare billing practices, pursues employee buyouts and potential layoffs, and … Read more

Bluebird Bio gene therapy sells itself to Carlyle and SK Capital

Sopa Images | Lightrocket | Getty Images Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money. … Read more

Hims & Hers to offer at-home blood draws, lean into peptides

The New York Stock Exchange with a Hims & Hers Health banner is pictured in the Manhattan borough of New York City. Carlo Allegri | Reuters Hims & Hers Health announced Wednesday it has acquired New Jersey-based at-home lab testing facility Trybe Labs. The deal will allow the telehealth company to offer at-home blood draws … Read more

UnitedHealthcare offers buyouts, could pursue layoffs

A general view outside the United Healthcare corporate headquarters on December 4, 2024 in Minnetonka, Minnesota.  Stephen Maturen | Getty Images UnitedHealthcare is offering certain employees in its benefits operations unit the option to accept buyouts if they quit by March 3, following a tumultuous year for the insurance giant, CNBC has learned. Those who … Read more

Measles outbreak grows bigger in rural Texas, and officials expect more cases

A vial of the measles, mumps, and rubella (MMR) vaccine is pictured at the International Community Health Services clinic in Seattle, Washington. Lindsey Wasson | Reuters At least 58 new cases of measles have been reported across northwest Texas in recent weeks, state health officials said Tuesday, in a “highly contagious” outbreak that might be linked to … Read more

Sickle cell gene therapies push health plans toward new payment models

Starting in his early teens, Deshawn “DJ” Chow wasn’t sure he’d ever be able to live a normal life. Crushing pain episodes brought on by his sickle cell disease were getting progressively worse.    “It’s just been hard skipping school and always being in and out of the hospital,” the 19-year-old said. “And just severe … Read more

Moderna (MRNA) Q4 earnings 2024

Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its Covid vaccine falls.  It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline … Read more